Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 23 May, 2014 and appeared in  CardiovascularMedicationBG ControlType 2 DiabetesInsulinIssue 730

Intensive Insulin Therapy Prolongs Life in Post-Acute Myocardial Infarction Diabetes Patients

Intensive insulin treatment extended life by more than two years after acute myocardial infarction (AMI) in patients with diabetes compared with standard treatment....

Advertisement

Researchers from the Karolinska Institute followed 620 patients with type 2 diabetes, beginning in 1990. Patients who were admitted to hospital with a suspected heart attack received an insulin-glucose infusion for at least 24 hours, followed by insulin injection four times a day for at least 3 months or standard glucose-lowering treatment, which only rarely involved insulin, for 1 year.
During the 20-year study period, most of the patients died of some cause. Results indicate, however, that those who received intensified insulin treatment during the trial survived a median of 2.3 years longer compared with those who received standard treatment.
The effect was apparent for at least 8 years after randomization before leveling off, according to the study. The greatest benefit from the intensive insulin treatment was for patients who appeared to be at low cardiovascular risk, were less than 70 years old, had no history of heart attack or congestive heart failure, and had not previously had insulin therapy.
The authors note that, although the results clearly show a benefit of intensive insulin treatment after a heart attack in patients with type 2 diabetes, the effect on survival is probably greater than if the trial was started today. The reason, they explain, is because of advances in conventional treatment of patients with type 2 diabetes and cardiovascular complications, including statins and angiotensin-converting-enzyme inhibitors.
Practice Pearls:

  • Those who received intensified insulin treatment during the trial survived a median of 2.3 years longer
  • The results show a benefit of intensive insulin treatment after a heart attack in patients with type 2 diabetes

The report, based on long-term follow-up of the DIGAMI 1 trial -- a landmark study of type 2 diabetes in Sweden -- was published recently in The Lancet Diabetes &Endocrinology, May 2014 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  CardiovascularMedicationBG ControlType 2 DiabetesInsulinIssue 730

Past five issues: Issue 747 | Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
Sensor Implant Measures Blood pH in Type 1 Diabetes
Posted August 29, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control